156 related articles for article (PubMed ID: 17077321)
1. Evidence for the multimeric structure of ferroportin.
De Domenico I; Ward DM; Musci G; Kaplan J
Blood; 2007 Mar; 109(5):2205-9. PubMed ID: 17077321
[TBL] [Abstract][Full Text] [Related]
2. The molecular basis of ferroportin-linked hemochromatosis.
De Domenico I; Ward DM; Nemeth E; Vaughn MB; Musci G; Ganz T; Kaplan J
Proc Natl Acad Sci U S A; 2005 Jun; 102(25):8955-60. PubMed ID: 15956209
[TBL] [Abstract][Full Text] [Related]
3. The flatiron mutation in mouse ferroportin acts as a dominant negative to cause ferroportin disease.
Zohn IE; De Domenico I; Pollock A; Ward DM; Goodman JF; Liang X; Sanchez AJ; Niswander L; Kaplan J
Blood; 2007 May; 109(10):4174-80. PubMed ID: 17289807
[TBL] [Abstract][Full Text] [Related]
4. Evidence for dimerization of ferroportin in a human hepatic cell line using proximity ligation assays.
Rishi G; Secondes ES; Wallace DF; Subramaniam VN
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32301493
[TBL] [Abstract][Full Text] [Related]
5. Wild-type and mutant ferroportins do not form oligomers in transfected cells.
Gonçalves AS; Muzeau F; Blaybel R; Hetet G; Driss F; Delaby C; Canonne-Hergaux F; Beaumont C
Biochem J; 2006 Jun; 396(2):265-75. PubMed ID: 16457665
[TBL] [Abstract][Full Text] [Related]
6. Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin.
Aschemeyer S; Qiao B; Stefanova D; Valore EV; Sek AC; Ruwe TA; Vieth KR; Jung G; Casu C; Rivella S; Jormakka M; Mackenzie B; Ganz T; Nemeth E
Blood; 2018 Feb; 131(8):899-910. PubMed ID: 29237594
[TBL] [Abstract][Full Text] [Related]
7. Ferroportin diseases: functional studies, a link between genetic and clinical phenotype.
Détivaud L; Island ML; Jouanolle AM; Ropert M; Bardou-Jacquet E; Le Lan C; Mosser A; Leroyer P; Deugnier Y; David V; Brissot P; Loréal O
Hum Mutat; 2013 Nov; 34(11):1529-36. PubMed ID: 23943237
[TBL] [Abstract][Full Text] [Related]
8. In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations.
Schimanski LM; Drakesmith H; Merryweather-Clarke AT; Viprakasit V; Edwards JP; Sweetland E; Bastin JM; Cowley D; Chinthammitr Y; Robson KJ; Townsend AR
Blood; 2005 May; 105(10):4096-102. PubMed ID: 15692071
[TBL] [Abstract][Full Text] [Related]
9. A disease-causing mutation K240E disrupts ferroportin trafficking by SUMO (ferroportin SUMOylation).
Bayele HK; Srai SKS
Biochem Biophys Rep; 2021 Mar; 25():100873. PubMed ID: 33490642
[TBL] [Abstract][Full Text] [Related]
10. Calcium and IL-6 regulate the anterograde trafficking and plasma membrane residence of the iron exporter ferroportin to modulate iron efflux.
Rosenblum SL; Bailey DK; Kosman DJ
J Biol Chem; 2024 Jun; 300(6):107348. PubMed ID: 38718866
[TBL] [Abstract][Full Text] [Related]
11. Fluorescence resonance energy transfer links membrane ferroportin, hephaestin but not ferroportin, amyloid precursor protein complex with iron efflux.
Dlouhy AC; Bailey DK; Steimle BL; Parker HV; Kosman DJ
J Biol Chem; 2019 Mar; 294(11):4202-4214. PubMed ID: 30647129
[TBL] [Abstract][Full Text] [Related]
12. Myeloid-specific deletion of ferroportin impairs macrophage bioenergetics but is disconnected from systemic insulin action in adult mice.
Winn NC; Wolf EM; Cottam MA; Bhanot M; Hasty AH
Am J Physiol Endocrinol Metab; 2021 Sep; 321(3):E376-E391. PubMed ID: 34338042
[TBL] [Abstract][Full Text] [Related]
13. Effect of ferroportin polymorphism on iron homeostasis and infection.
Kasvosve I
Clin Chim Acta; 2013 Feb; 416():20-5. PubMed ID: 23178444
[TBL] [Abstract][Full Text] [Related]
14. The Role of Copper in the Regulation of Ferroportin Expression in Macrophages.
Jończy A; Mazgaj R; Smuda E; Żelazowska B; Kopeć Z; Starzyński RR; Lipiński P
Cells; 2021 Aug; 10(9):. PubMed ID: 34571908
[TBL] [Abstract][Full Text] [Related]
15. Low ferroportin expression in AML is correlated with good risk cytogenetics, improved outcomes and increased sensitivity to chemotherapy.
Gasparetto M; Pei S; Minhajuddin M; Stevens B; Smith CA; Seligman P
Leuk Res; 2019 May; 80():1-10. PubMed ID: 30852438
[TBL] [Abstract][Full Text] [Related]
16. Molecular and clinical correlates in iron overload associated with mutations in ferroportin.
De Domenico I; McVey Ward D; Nemeth E; Ganz T; Corradini E; Ferrara F; Musci G; Pietrangelo A; Kaplan J
Haematologica; 2006 Aug; 91(8):1092-5. PubMed ID: 16885049
[TBL] [Abstract][Full Text] [Related]
17. Estrogen contributes to regulating iron metabolism through governing ferroportin signaling via an estrogen response element.
Qian Y; Yin C; Chen Y; Zhang S; Jiang L; Wang F; Zhao M; Liu S
Cell Signal; 2015 May; 27(5):934-42. PubMed ID: 25660146
[TBL] [Abstract][Full Text] [Related]
18. Iron supply determines apical/basolateral membrane distribution of intestinal iron transporters DMT1 and ferroportin 1.
Núñez MT; Tapia V; Rojas A; Aguirre P; Gómez F; Nualart F
Am J Physiol Cell Physiol; 2010 Mar; 298(3):C477-85. PubMed ID: 20007457
[TBL] [Abstract][Full Text] [Related]
19. Myeloid zinc-finger 1 (MZF-1) suppresses prostate tumor growth through enforcing ferroportin-conducted iron egress.
Chen Y; Zhang Z; Yang K; Du J; Xu Y; Liu S
Oncogene; 2015 Jul; 34(29):3839-47. PubMed ID: 25284586
[TBL] [Abstract][Full Text] [Related]
20. Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin.
De Domenico I; Ward DM; di Patti MC; Jeong SY; David S; Musci G; Kaplan J
EMBO J; 2007 Jun; 26(12):2823-31. PubMed ID: 17541408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
